Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q1 2024 ▲▼ | Q2 2024 ▲▼ | Change ▲▼ | Q1 2024 ▲▼ | Q2 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Liquidia Corporation(LQDA) | 10,360,945 | 10,360,945 | 0 | $152.82M | $124.33M | 29.05% | -$28.49M |
| Alimera Sciences Inc | 16,835,154 | 16,835,154 | 0 | $65.66M | $93.60M | 21.87% | +$27.95M |
| Anika Therapeutics Inc | 1,435,993 | 1,435,993 | 0 | $36.47M | $36.37M | 8.50% | -$100.5K |
| Exelixis, Inc.(EXEL) | 1,100,730 | 1,525,730 | +425,000 | $26.12M | $34.28M | 8.01% | +$8.16M |
| BioCryst Pharmaceuticals, Inc.(BCRX) | 758,502 | 4,598,737 | +3,840,235 | $3.85M | $28.42M | 6.64% | +$24.57M |
| Verona Pharma PlcADS | 1,296,447 | 1,843,756 | +547,309 | $20.86M | $26.66M | 6.23% | +$5.80M |
| Evolus, Inc.(EOLS) | 1,888,881 | 2,167,790 | +278,909 | $26.44M | $23.52M | 5.50% | -$2.92M |
| Agios Pharmaceuticals, Inc.(AGIO) | 484,711 | 514,711 | +30,000 | $14.17M | $22.19M | 5.19% | +$8.02M |
| Enanta Pharmaceuticals, Inc.(ENTA) | 858,070 | 1,042,889 | +184,819 | $14.98M | $13.53M | 3.16% | -$1.46M |
| Mineralys Therapeutics, Inc.(MLYS) | 0 | 745,758 | +745,758 | $0 | $8.73M | 2.04% | +$8.73M |
| Y-Mabs Therapeutics Inc | 587,276 | 582,078 | -5,198 | $9.55M | $7.03M | 1.64% | -$2.52M |
| NovaBridge BiosciencesADS(NBP) | 756,538 | 3,374,791 | +2,618,253 | $1.41M | $5.64M | 1.32% | +$4.23M |
| Outlook Therapeutics, Inc.(OTLK) | 500,000 | 500,000 | 0 | $5.97M | $3.69M | 0.86% | -$2.28M |